Heart failure drug dosing could be simplified safely
- A new study suggests that dosing of heart failure medication can be safely simplified.
- The study found that patients could start vericiguat, a medication for heart failure with reduced ejection fraction, at a dose of 5 mg instead of the conventional 2.5 mg starting dose.
- Reducing the number of titration steps from three to two could help overcome “clinical inertia” and improve patient outcomes, as most patients never achieve target doses of recommended heart failure medications.
- The study enrolled 106 patients across seven countries who started the higher dose of vericiguat over two weeks, with safety measures for both groups being comparable.
- Simplifying the initiation and titration process may help overcome logistical challenges in real-world settings, such as limited appointment availability and time per patient, to improve the quality of care patients receive.
A new study suggests dosing of heart failure medication can be safely simplified.
An estimated 32 million people globally have heart failure with reduced ejection fraction, a condition where the lower left chamber of the heart does a poor job of pumping blood to the rest of the body.
While there are approved medications for the condition, not all providers escalate patient doses to target levels, increasing the risk of adverse events, hospitalizations, and death.
In a study led by a Duke scientist—presented at a late-breaking research session on May 17 at the 2025 European Society of Cardiology conference and appearing in the European Journal of Heart Failure—researchers found patients could safely start vericiguat (a medication for heart failure with reduced ejection fraction) at a dose of 5 mg instead of the conventional 2.5 mg starting dose, streamlining the process to reach target dosing from three steps to two.
Stephen Greene is the corresponding author of the study and associate professor in the Department of Medicine in the Duke University School of Medicine. He says reducing the steps to target dosing could help overcome clinical inertia.
“In real-world practice, most patients never achieve the target doses of recommended heart failure medications,” Greene says.
“Despite clinic visit after clinic visit, medication changes are relatively rare. If titration of heart failure medications is rare in clinical practice, then it stands to reason that reducing the number of titration steps would give our patients a better chance to ultimately achieve target dosing.”
The study enrolled 106 patients across seven countries who started the 5 mg dose of vericiguat over the course of two weeks. The researchers compared safety and tolerability of the higher dose group with those of study participants receiving the current dosing standard. The study found safety measures for both groups to be comparable, with more than 9 out of 10 patients safely tolerating initiation of vericiguat at the higher 5 mg starting dose.
“I think simplicity is the key when we talk about implementation of heart failure medications in clinical practice,” Greene says.
“Real-world settings come with logistical challenges, and oftentimes clinics are very busy with limited appointment availability and limited available time per patient. These factors unfortunately set a stage for clinical inertia and for patients to go without important medication changes. Simplifying the way that we initiate and titrate heart failure medications may help overcome this and improve the quality of care our patients receive.”
Funding for the study came from Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Both companies are makers of vericiguat.
Source: Duke University
The post Heart failure drug dosing could be simplified safely appeared first on Futurity.